Navigation Links
In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop
Date:10/7/2008

CAMBRIDGE, Mass., Oct. 7 /PRNewswire/ -- Taligen Therapeutics Inc. today announced that in vivo data on several of the Company's pipeline candidates were presented at the XXII International Complement Workshop in Basel, Switzerland. The data highlighted the candidates' efficacy in several animal models of complement-mediated diseases.

"These highlighted presentations, as well as several in vitro studies presented at the conference, reveal the deep expertise and expanding knowledge base within the complement research community," said Michael Holers, M.D., chief scientific officer of Taligen Therapeutics. "The work, not only from our laboratory but from the laboratories of our collaborators, is unlocking the mechanisms of immunomodulation and enabling Taligen to direct the development of new product candidates and test them in a variety of animal models as a precursor to their clinical development."

"The opportunity to further evaluate Taligen's TT30 compound in our research activities has been invaluable in our characterization of the effects of modulation of the complement system on animal models of human disease," said Steve Tomlinson, Ph.D. and principal investigator of several studies presented at the complement meeting. "Our results in the MRL lupus model in collaboration with Dr. Gary Gilkeson's group now show that targeted complement inhibition using TT30 leads to both local control of inflammation as well as a substantial decrease in the autoimmune response in vivo. No other type of compound has this dual profile of activity. I also believe these CR2-targeted compounds will help future research in the lupus area and hopefully provide therapeutic options for patients."

Key findings from several of the studies testing Taligen's product candidates are highlighted below:

Data support targeting the alternative complement pathway using TT30 as an immunomodulatory compound for treating complement-mediated diseases

In vivo st
'/>"/>

SOURCE Taligen Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
2. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
3. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
4. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
5. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
6. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
7. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
10. Tobira Therapeutics Inc. Receives US Patent for TBR-652
11. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Today the U.S. Food ... Bexsero® for the prevention of serogroup B meningococcal ... and Pfizer,s vaccine Trumenba®, which received FDA approval in ... this devastating disease. "I have heard ...
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... Jan. 23, 2015 More than a third of reproductive-aged ... those with private insurance, filled a prescription for an opioid ... in this week,s Morbidity and Mortality Weekly Report (MMWR). ... to treat moderate to severe pain.  They are also found ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... risk of breast cancer recurrence , , ... taking tamoxifen with certain antidepressants more than doubled the ... medications. The antidepressants inhibit an enzyme, CYP2D6, which helps ... ) , , The study was conducted ...
... of Clinical Oncology Annual MeetingAbstracts: 5033, 3560ORLANDO, Fla., ... Phase I and II trials of BAY 73-4506, ... in multiple tumor types. These data were ... American Society of Clinical Oncology (ASCO)."Bayer is committed ...
Cached Medicine Technology:New Research Shows Antidepressants May Thwart Breast Cancer Treatment 2New Research Shows Antidepressants May Thwart Breast Cancer Treatment 3Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506 2Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506 3
(Date:1/22/2015)... 2015 The U.S. Pharmacopeial Convention is ... of Clinical Pharmacy Services at North Carolina State’s College ... the 2015 Beal Award for Distinguished Volunteer Service—the organization’s ... on the contributions of volunteer experts to direct its ...
(Date:1/22/2015)... 22, 2015 The City of West Hollywood hosted ... to commemorate the 42nd anniversary of the Supreme Court decision Roe ... been 42 years since the Roe vs. Wade decision and the ... present as ever,” said City of West Hollywood Councilmember Abbe Land. ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, AZ has ... (PPHA). The PPHA's passion for others' well-being and shared ... treated for obstructive sleep apnea (OSA) has propelled them into ... the valley. The most recent plans for an event will ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... Nanotechnology is the use of particles which are very ... pose a health hazard. // The petition was raised ... Administration (FDA) to strengthen its regulation of sunscreens that ... are thought to cause inflammatory and immune responses in ...
... the situation in case of an outbreak of bird flu ... preparation.// They are asked to appoint a bird flu tsar. ... have to look harder at immediate practical measures and implement ... ,He said that their problem is that the decision-making was ...
... outlined programs to ease bureaucratic procedures in the department. // ... by the minister in Launceston this morning to 200 of ... is to reduce the number of approvals needed for day-to-day ... within the bureaucratic process and we're addressing those,’ she said. ...
... has been found that cardiovascular clinical trials published between ... whether they were funded by for-profit //organizations or by ... the May 17 issue of JAMA. ,Surveys ... awareness in the medical community that trials funded by ...
... not yet ascertained the top floors of the Melbourne office ... identify the cause of illnesses.// ,Tests on radiofrequency ... establish any link as yet to the seven cases of ... ,Five of these seven cases were employees who had worked ...
... is associated with the formation of blood clots during long ... is thought to be, reveals a new study. ,The ... people, while sitting in cramped places, that cause a reduction ... the formation of clots. This is perhaps the reason why ...
Cached Medicine News:Health News:Results of Clinical Trials Vary According to Source of Funding 2
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Portless Sheath Introducers...
Introducer Sheath Designed for Vascular Access...
Used to introduce balloon, electrode, closed or non-tapered end and,other catheters....
Medicine Products: